Jocil (JOCIL)
Asset PlayScore breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹146.28 |
| Market Cap | ₹129.91 Cr |
| P/E Ratio | 15.64 |
| ROCE | 0.71% |
| ROE | —% |
| Dividend Yield | 2.34% |
| Profit Growth | -2% |
| Debt/Equity | 0.03 |
| Sales Growth | -6.3% |
| Promoter Holding | 55.02% |
| 52-Week Range | ₹91.25 — ₹174 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹239.92 |
Strengths
- Price-to-book of 0.54: stock at ₹126.40 vs book value ₹236.09
- Very low debt: D/E of 0.03, minimal balance sheet risk
- Promoter holding of 55.02% aligns ownership with minority shareholders
- Piotroski F-Score of 7/9 and 19.45% sales growth suggest improving operations
- Latest quarter is positive: ₹2 Cr net profit on ₹263 Cr sales
Concerns
- ROCE of only 0.71% means capital employed is earning almost no return
- Latest quarter net margin is under 1%: ₹2 Cr profit on ₹263 Cr sales
- P/E of 19.37 on depressed earnings is not obviously cheap; 160% profit growth stems from a low base
- Commodity chemical business likely lacks pricing power, and the wide 52-week range signals volatility
AI Analysis
Let me start with what I like. Jocil sells at ₹126.40 while its book value is ₹236.09—a price-to-book of 0.54. The balance sheet is conservatively run, with debt-to-equity of 0.03 and promoters owning 55%. That is the kind of margin-of-safety starting point Graham would notice. But a cheap price cannot turn a poor business into a wonderful one. Jocil is a commodity chemical company. It has no pricing power; the market decides the price. ROCE is only 0.71%, meaning the capital employed is not earning anywhere near a satisfactory return. The latest quarter shows sales of ₹263 crore but net profit of just ₹2 crore. That is less than a 1% net margin. The 160% profit growth sounds impressive, but it is off a very low base, and the 19.37 P/E on those small earnings is not a bargain. The PEG of 0.22 is a statistic, not a philosophy. Sales grew 19.45%, and the Piotroski score of 7 suggests improving financial health, so there may be a cyclical or operational recovery underway. But I would be buying this for the assets, not for the earning power. In an asset play, I must be sure liquidation or earning power will close the gap between ₹126 and ₹236 of book value. Until I see sustained returns on capital, better margins, and a clear catalyst, I remain cautious. This is not the kind of predictable compounder Buffett loves; it is a potential bargain-bin special that demands constant attention.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer